REGENXBIO (Series C)
Funding Details
Awarder
Inbox
Date Award
January 21, 2015
Vertical
Gene Therapy
Funding URL
View Funding Page
Funding Amount
$30,000,000
Company Info
Organizations Involved
Baxter Healthcare, Fondazione Telethon, Audentes Therapeutics, Lysogene, Esteve, AveXis, AAVLife, Voyager Therapeutics
Founders
Ken Mills
Market
Severe diseases with serious unmet needs
Location
Washington, DC, United States
Coinvestors
Brookside Capital, Deerfield Management Company, L.P., FoxKiser, Venrock
Company Description

REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.

Links
WebsiteCrunchbaseLinkedInTwitter
Back to HomeBack to Gene Therapy DealsView Funding Announcement